Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson’s Disease Demonstrated by Proton Magnetic Resonance Spectroscopy
Joint Authors
Aasly, Jan O.
Sæther, Oddbjørn
Johansen, Krisztina K.
Bathen, Tone F.
Giskeødegård, Guro F.
White, Linda R.
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-08-18
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Background.
Parkinson’s disease (PD) remains a clinical diagnosis and biomarkers are needed to detect the disease as early as possible.
Genetically determined PD provides an opportunity for studying metabolic differences in connection with disease development.
Objectives.
To study the levels of intermediary metabolites in cerebrospinal fluid (CSF) from patients with PD, either of sporadic type or in carriers of the LRRK2 p.G2019S mutation.
Methods.
Results from patients with sporadic PD or LRRK2-PD were compared with asymptomatic LRRK2 mutation carriers and healthy control individuals.
CSF was analysed by proton MR spectroscopy (1H-MRS) giving reliable results for 16 intermediary metabolites.
Partial least squares discriminant analysis (PLS-DA) was applied to study group differences.
Results.
PLS-DA distinguished PD patients from healthy individuals based on the metabolites identified in CSF, with 2-hydroxybutyrate, glutamine, and dimethyl sulphone largely contributing to the separations.
Conclusion.
Speculatively, all three metabolites could alter concentration in response to metabolic changes connected with neurodegeneration; glutamine as a means of removing excess nitrogen from brain, dimethyl sulphone as an anti-inflammatory agent, and 2-hydroxybutyrate in connection with altered glutathione metabolism.
Potentially, 1H-MRS is a promising tool for identifying novel biomarkers for PD.
American Psychological Association (APA)
Aasly, Jan O.& Sæther, Oddbjørn& Johansen, Krisztina K.& Bathen, Tone F.& Giskeødegård, Guro F.& White, Linda R.. 2015. Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson’s Disease Demonstrated by Proton Magnetic Resonance Spectroscopy. Parkinson’s Disease،Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1075859
Modern Language Association (MLA)
Aasly, Jan O.…[et al.]. Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson’s Disease Demonstrated by Proton Magnetic Resonance Spectroscopy. Parkinson’s Disease No. 2015 (2015), pp.1-9.
https://search.emarefa.net/detail/BIM-1075859
American Medical Association (AMA)
Aasly, Jan O.& Sæther, Oddbjørn& Johansen, Krisztina K.& Bathen, Tone F.& Giskeødegård, Guro F.& White, Linda R.. Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson’s Disease Demonstrated by Proton Magnetic Resonance Spectroscopy. Parkinson’s Disease. 2015. Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1075859
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1075859